– Results highlight PPMP as a tool for identifying most promising drug combinations for patients in high unmet medical needs, including JMML – JMML is a rare, aggressive pediatric malignancy for which ...
Indiana University School of Medicine researchers have identified a promising new combination of drugs to treat juvenile myelomonocytic leukemia (JMML), a rare form of blood cancer that affects ...
Juvenile myelomonocytic leukemia (JMML) is a rare type of blood cancer that usually affects young children. It occurs when monocytes, a type of white blood cell, grow uncontrollably. JMML accounts for ...
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric malignancy with myelodysplastic and myeloproliferative features. Curative treatment is restricted to hematopoietic stem-cell ...
Bottom Line: The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II ...
Indiana University School of Medicine researchers have identified a promising new combination of drugs to treat juvenile myelomonocytic leukemia (JMML), a rare form of blood cancer that affects ...
– Article Published in November 9th Issue of ASCO’s Journal of Clinical Oncology Precision Oncology (JCO PO) – – Results highlight PPMP as a tool for identifying most promising drug combinations for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results